<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004836'>Acute promyelocytic leukemia</z:hpo> (APL) is a subtype of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) that is characterized by peculiar clinical and biologic features, including severe <z:e sem="disease" ids="C0019087" disease_type="Disease or Syndrome" abbrv="">hemorrhagic diathesis</z:e>, specific recurrent chromosomal aberration, and distinct morphologic features with predominant pathologic promyelocytes </plain></SENT>
<SENT sid="1" pm="."><plain>A reciprocal translocation involving chromosomes 15 and 17, t(15;17)(q22;q21), is a characteristic feature of APL that represents approximately 5-8% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The rearranged gene created by this translocation encodes a chimeric protein PML-RARA that is a transcriptional repressor </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast to other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> subtypes, APL is particularly sensitive to treatment with <z:hpo ids='HP_0000001'>all</z:hpo> trans-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) combined with chemotherapy, converting this once fatal <z:hpo ids='HP_0001909'>leukemia</z:hpo> to a highly curable disease </plain></SENT>
<SENT sid="4" pm="."><plain>Nonetheless, therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been reported as a rare complication of chemotherapy in APL </plain></SENT>
<SENT sid="5" pm="."><plain>Of 30 APL cases described as t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in the literature, only 1 case relapsed as <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> with t(3;21)(q26;q22) </plain></SENT>
<SENT sid="6" pm="."><plain>Here we describe a rare case of APL relapsing as <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> with t(3;21)(q26;q22) and clinically characterize this patient using the RUNX1 (previously AML1)-MDS1-EVI1 fusion transcript (with follow-up for 55 months), and review the relevant literature </plain></SENT>
</text></document>